Cargando…

Listeriosis in a Metropolitan Hospital: Is Targeted Therapy a Risk Factor for Infection?

Targeted therapies are widely used for treatment of autoimmune diseases as well as solid organ and hematological malignancies. Various opportunistic infections have been described in patients on targeted therapies. Although case reports or a few case series of listeriosis have been reported to be as...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Fanfan, Lo, Simon K. F., Lau, Susanna K. P., Woo, Patrick C. Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100811/
https://www.ncbi.nlm.nih.gov/pubmed/35572995
http://dx.doi.org/10.3389/fmed.2022.888038
_version_ 1784706938756399104
author Xing, Fanfan
Lo, Simon K. F.
Lau, Susanna K. P.
Woo, Patrick C. Y.
author_facet Xing, Fanfan
Lo, Simon K. F.
Lau, Susanna K. P.
Woo, Patrick C. Y.
author_sort Xing, Fanfan
collection PubMed
description Targeted therapies are widely used for treatment of autoimmune diseases as well as solid organ and hematological malignancies. Various opportunistic infections have been described in patients on targeted therapies. Although case reports or a few case series of listeriosis have been reported to be associated with targeted therapy, most of the cases were related to anti-tumor necrosis factor-α monoclonal antibody. In this study, we describe the epidemiological and clinical profiles of listeriosis in a tertiary hospital in Shenzhen, a Southern Chinese metropolitan city in China. During the 9-year-and-6-month study period, a total of five cases of listeriosis were recorded and all of them had Listeria monocytogenes bacteremia. All five patients had predisposing factors, including corticosteroid (n = 3), targeted therapy (n = 2), pregnancy (n = 2) and anti-interferon gamma autoantibody (n = 1). The two patients who had targeted therapy during their course of cancer treatment received inhibitors of the epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) pathway. The first one was a 52-year-old woman with metastatic adenocarcinoma of the lung. She was given gefitinib (EGFR tyrosine kinase inhibitor), osimertinib (third-generation EGFR tyrosine kinase inhibitor) and afatinib (tyrosine kinase inhibitor that can bind to EGFR, HER2 and HER4). The second one was a 40-year-old woman with carcinoma of the breast with brain metastasis. She was given trastuzumab (anti-HER2 monoclonal antibody) and lapatinib (dual tyrosine kinase inhibitor of the EGFR/HER2 pathway). These two patients represent the second and third reports of listeria infections associated with EGFR/HER2 pathway inhibitors in the literature. Targeted therapy is an important predisposing factor for listeriosis. Listeria infection is an important differential diagnosis in patients on targeted therapy who present with sepsis and/or central nervous system infection, and the use of antibiotic regimens that cover listeria is crucial for empirical treatment. Avoidance of high-risk food items in these patients is important for the prevention of listeriosis.
format Online
Article
Text
id pubmed-9100811
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91008112022-05-14 Listeriosis in a Metropolitan Hospital: Is Targeted Therapy a Risk Factor for Infection? Xing, Fanfan Lo, Simon K. F. Lau, Susanna K. P. Woo, Patrick C. Y. Front Med (Lausanne) Medicine Targeted therapies are widely used for treatment of autoimmune diseases as well as solid organ and hematological malignancies. Various opportunistic infections have been described in patients on targeted therapies. Although case reports or a few case series of listeriosis have been reported to be associated with targeted therapy, most of the cases were related to anti-tumor necrosis factor-α monoclonal antibody. In this study, we describe the epidemiological and clinical profiles of listeriosis in a tertiary hospital in Shenzhen, a Southern Chinese metropolitan city in China. During the 9-year-and-6-month study period, a total of five cases of listeriosis were recorded and all of them had Listeria monocytogenes bacteremia. All five patients had predisposing factors, including corticosteroid (n = 3), targeted therapy (n = 2), pregnancy (n = 2) and anti-interferon gamma autoantibody (n = 1). The two patients who had targeted therapy during their course of cancer treatment received inhibitors of the epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) pathway. The first one was a 52-year-old woman with metastatic adenocarcinoma of the lung. She was given gefitinib (EGFR tyrosine kinase inhibitor), osimertinib (third-generation EGFR tyrosine kinase inhibitor) and afatinib (tyrosine kinase inhibitor that can bind to EGFR, HER2 and HER4). The second one was a 40-year-old woman with carcinoma of the breast with brain metastasis. She was given trastuzumab (anti-HER2 monoclonal antibody) and lapatinib (dual tyrosine kinase inhibitor of the EGFR/HER2 pathway). These two patients represent the second and third reports of listeria infections associated with EGFR/HER2 pathway inhibitors in the literature. Targeted therapy is an important predisposing factor for listeriosis. Listeria infection is an important differential diagnosis in patients on targeted therapy who present with sepsis and/or central nervous system infection, and the use of antibiotic regimens that cover listeria is crucial for empirical treatment. Avoidance of high-risk food items in these patients is important for the prevention of listeriosis. Frontiers Media S.A. 2022-04-29 /pmc/articles/PMC9100811/ /pubmed/35572995 http://dx.doi.org/10.3389/fmed.2022.888038 Text en Copyright © 2022 Xing, Lo, Lau and Woo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Xing, Fanfan
Lo, Simon K. F.
Lau, Susanna K. P.
Woo, Patrick C. Y.
Listeriosis in a Metropolitan Hospital: Is Targeted Therapy a Risk Factor for Infection?
title Listeriosis in a Metropolitan Hospital: Is Targeted Therapy a Risk Factor for Infection?
title_full Listeriosis in a Metropolitan Hospital: Is Targeted Therapy a Risk Factor for Infection?
title_fullStr Listeriosis in a Metropolitan Hospital: Is Targeted Therapy a Risk Factor for Infection?
title_full_unstemmed Listeriosis in a Metropolitan Hospital: Is Targeted Therapy a Risk Factor for Infection?
title_short Listeriosis in a Metropolitan Hospital: Is Targeted Therapy a Risk Factor for Infection?
title_sort listeriosis in a metropolitan hospital: is targeted therapy a risk factor for infection?
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100811/
https://www.ncbi.nlm.nih.gov/pubmed/35572995
http://dx.doi.org/10.3389/fmed.2022.888038
work_keys_str_mv AT xingfanfan listeriosisinametropolitanhospitalistargetedtherapyariskfactorforinfection
AT losimonkf listeriosisinametropolitanhospitalistargetedtherapyariskfactorforinfection
AT laususannakp listeriosisinametropolitanhospitalistargetedtherapyariskfactorforinfection
AT woopatrickcy listeriosisinametropolitanhospitalistargetedtherapyariskfactorforinfection